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tude below that necessary to visualize synapses, it is difficult
to ascertain synaptic BuChE unless a unique and exclusive
synaptic localization of the ligand is demonstrated by inde-
pendent means.
Based on the above considerations, it is difficult to reach
convincing conclusions regarding synaptic BuChE in AD us-
ing the positron emission tomography data presented.
1Brain-Mind Project and University of Miami School of
Medicine, Miami, FL, 2Departments of Medicine, Anatomy
and Neurobiology, Dalhousie University, Halifax, Nova
Scotia, Canada, 3Drug Design & Development Section,
Laboratory of Neurosciences, Intramural Research Program,
National Institute on Aging, Baltimore, MD, and 4Laboratory
for Neurodegenerative and Aging Research, Harvard Medical
School, Beth Israel Deaconess Medical Center, Boston, MA
References
1. Kuhl DE, Koeppe RA, Snyder SE, et al. In vivo butyrylcholines-
terase activity is not increased in Alzheimer’s disease synapses.
Ann Neurol 2006;59:13–20.
2. Snyder SE, Gunpundi N, Sherman PS, et al. Radiolabeled
substrates: in vitro methods for determining structure-activity re-
lationships and identification of a positron emission tomography
radiopharmaceutical for in vivo measurement of butyrylcholines-
terase activity. J Cereb Blood Flow Metab 2001;21:132–143.
3. Silver A. The biology of cholinesterases. Amsterdam: Elsevier,
1974.
4. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in
brain cholinesterase in senile dementia of Alzheimer’s type. Neu-
ropathol Appl Neurobiol 1978;4:273–277.
5. Geula C, Mesulam M-M. Cholinesterases and the pathology of
Alzheimer’s disease. Alzheimer Dis Assoc Disord 1995;9:23–28.
DOI: 10.1002/ana.20926
Imaging Butyrylcholinesterase Activity in
Alzheimer’s Disease
David E. Kuhl, MD,1 Robert A. Koeppe, PhD,1
Scott E. Snyder, PhD,1 Satoshi Minoshima, MD, PhD,2
Kirk A. Frey, MD, PhD,1,3 and Michael R. Kilbourn, PhD1
It is unverified that the ligand 1-[11C]methyl-4-piperidinyl
n-butyrate ([11C]BMP) is not a substrate for acetylcholines-
terase (AChE). We identified [11C]BMP based on specificity
determined by in vitro assay using nonhuman esterases.1
We1 and others2 have demonstrated in vitro that neither
BMP nor any of the other longer chain 1-methyl-4-
piperidinyl esters shows cleavage by AChE, even at enzyme
concentrations of 100U/ml and incubation times as long as
60 minutes. In no references were butyrate esters found to be
substrates for AChE in any species. It is unlikely that cleav-
age of [11C]BMP by AChE occurs in human brain, particu-
larly within the time frame of a typical positron emission
tomography (PET) study.
Can low-resolution PET visualize synapse content? If PET
misses plaque-bound cholinesterase, how can it estimate syn-
apse cholinesterase? The PET method using [11C]BMP (see
Kuhl and colleagues3) provides estimates of butyrylcholines-
terase (BuChE) hydrolysis rates in vivo, not BuChE concen-
tration. This method is not merely measuring the distribu-
tion of the radiotracer from a static image, but rather is
based on the temporal kinetics of the radiotracer in vivo.
The limited resolution of PET (10mm in this study) is in-
sufficient to determine the histological location of [11C]BMP
cleavage. However, the PET measure is sensitive to BuChE
hydrolysis of [11C]BMP wherever it does occur within the
field of view, even when each of these multiple sites (syn-
apses, glia) is smaller than the resolution of the imaging sys-
tem. Other information is needed to inform the histological
location of hydrolysis.
For example, hydrolysis of acetylcholine is known to oc-
cur predominantly within cholinergic synapses by out-
wardly facing, membrane-anchored AChE and BuChE.4
These are the critical sites where acetylcholine is concen-
trated and to which inhibition therapy is targeted. We have
shown that PET methods quantify AChE or BuChE activ-
ities within tissue distributions that are accessible to system-
ically administered cholinesterase inhibitors and that match
regional distributions of AChE5 and BuChE.3 Conse-
quently, PET-measured AChE activity estimates activity in
cholinergic terminals, where AChE is known to be concen-
trated primarily. The distribution of BuChE activity is
known to be much more uniform, but does include the
cholinergic synapses.
Unlike tissue homogenate assays of postmortem AD brain,
our in vivo PET method could have been insensitive to sub-
stantial increases in sparse, but highly concentrated, dead foci
of plaque BuChE that were poorly perfused and distant from
cholinergic terminals. However, our in vivo method should
have detected in living AD brain any substantial increase in
BuChE activity that could have been associated with cholin-
ergic synapses, and it did not.
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